ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Los Angeles, CA, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Santa Monica, California, United States and 44 other locations

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Trilaciclib

Phase 2

G1 Therapeutics

Los Angeles, California, United States and 21 other locations

Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer

to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread...

Enrolling
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Drug: Ivermectin
Drug: Balstilmab

Phase 1, Phase 2

Yuan Yuan

Los Angeles, California, United States

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Los Angeles, California, United States and 49 other locations

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Santa Monica, California, United States and 23 other locations

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or afte...

Active, not recruiting
Triple Negative Breast Cancer
Procedure: SBRT
Biological: GI-4000

Phase 1, Phase 2

ImmunityBio
ImmunityBio

El Segundo, California, United States

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Los Angeles, California, United States and 216 other locations

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative br ...

Active, not recruiting
Anatomic Stage IV Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Biological: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody

Phase 1

City of Hope
City of Hope

Duarte, California, United States

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Los Angeles, California, United States and 144 other locations

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Burbank, California, United States and 199 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems